Chongqing bids $93M for Bilthoven

China's Chongqing Zhifei Biological Products has bid $93 million (€65 million) in an auction of Dutch vaccine maker Bilthoven Biologicals, a spin-off of the Netherlands Vaccine Institute. Report

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.